
Novo Says Women Lost 25% on CagriSema in Trial Analysis, With Differences by Menopause Stage
Notes de l’épisode
Novo Nordisk says women in its phase 3 REDEFINE 1 trial lost 25.0% of their body weight on average after 68 weeks on its investigational weekly injection CagriSema (cagrilintide plus semaglutide), compared with 3.0% on placebo, in a post hoc analysis presented at The Menopause Society 2026 Annual Meeting in San Diego. A second analysis grouped 1,902 women by menopausal stage: average weight loss was 26.7% in premenopausal, 24.8% in perimenopausal and 23.1% in postmenopausal women, versus about 2% on placebo. Both figures use the efficacy estimand, which assumes everyone stayed on treatment, and menopause status was assigned after the fact. Novo calls the findings hypothesis-generating. We cover what the numbers do and don't show, how the full trial population compared (22.7%), how the results line up with earlier tirzepatide analyses in women, the trial's side-effect and discontinuation rates, and where CagriSema stands: not approved, with an FDA decision expected in the fourth quarter of 2026. Sources: - Novo Nordisk press release (Oct 20, 2026): https://www.novonordisk-us.com/media/press-releases/cagrisema-redefine1-weight-loss-women-menopause.html - CNBC: https://www.cnbc.com/2026/10/20/novo-cagrisema-women-weight-loss-analysis.html - BioSpace: https://www.biospace.com/drug-development/novos-cagrisema-achieves-25-weight-loss-in-women-driven-by-younger-patients - Reuters, via ETPharma: https://pharma.economictimes.indiatimes.com/news/research-and-development/novos-cagrisema-helped-women-lose-25-of-weight-on-average-analysis-shows/135085769 Cover: original editorial image made for this episode; the pen shown is generic, not a real product. This show is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication. More at glp1newspaper.com
Tous les épisodes de GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News